PolyPeptide Group AG/Fr. PPGN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About PolyPeptide Group AG
PolyPeptide Group AG operates in the pharmaceutical industry, specializing in the development and manufacture of peptides for various applications. Headquartered in Zug, Switzerland, the company provides essential services and products for the pharmaceutical and biotechnology sectors, including custom peptide synthesis and generic peptide production. With a network of manufacturing facilities across Europe and the United States, PolyPeptide Group AG supports a global clientele. The company's strategic positioning is reinforced by its focus on innovation and quality, ensuring compliance with rigorous industry standards. PolyPeptide's competitive strength lies in its extensive expertise and capabilities in peptide synthesis, serving sectors ranging from therapeutic peptides to cosmetics.
- Ticker
- Fr. PPGN
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 1,460
- Headquarters
- Baar, Switzerland
- Website
- www.polypeptide.com
PPGN Metrics
BasicAdvanced
CHF 1.4B
103.12
CHF 0.41
1.00
-
Price and volume
Market cap
CHF 1.4B
Beta
1
52-week high
CHF 50.10
52-week low
CHF 21.80
Average daily volume
68K
Financial strength
Current ratio
1.642
Quick ratio
0.758
Long term debt to equity
0.349
Total debt to equity
0.425
Interest coverage (TTM)
4.16%
Profitability
EBITDA (TTM)
69.464
Gross margin (TTM)
22.86%
Net profit margin (TTM)
3.15%
Operating margin (TTM)
9.63%
Effective tax rate (TTM)
42.56%
Revenue per employee (TTM)
CHF 285,390
Management effectiveness
Return on assets (TTM)
3.38%
Return on equity (TTM)
4.24%
Valuation
Price to earnings (TTM)
103.116
Price to revenue (TTM)
3.247
Price to book
3.95
Price to tangible book (TTM)
4.02
Price to free cash flow (TTM)
-29.211
Free cash flow yield (TTM)
-3.42%
Free cash flow per share (TTM)
-1.44
Growth
Revenue change (TTM)
24.40%
Earnings per share change (TTM)
-142.49%
3-year revenue growth (CAGR)
18.02%
3-year earnings per share growth (CAGR)
-26.51%
What the Analysts think about PPGN
Analyst ratings (Buy, Hold, Sell) for PolyPeptide Group AG stock.
Analyst projections of the future price of PolyPeptide Group AG stock.
Bulls say / Bears say
H1 2026 revenue rose 41.6%, with metabolic therapeutics up 72.7%, and PolyPeptide lifted its full-year revenue-growth guidance to 25–30%. This points to strong demand translating into improved results. (PolyPeptide)
PolyPeptide supported 37 Phase III peptide programmes by mid-2026, roughly half of global synthetic-peptide Phase III activity. Progression of these programmes could create a substantial pipeline of future commercial manufacturing work. (Investing.com)
An Amylyx term sheet includes a US$30 million upfront capacity-reservation fee and minimum annual purchase quantities from 2028, subject to a definitive agreement. If completed, it would add customer-backed demand beyond the current growth cycle. (StockTitan)
H1 operating cash flow fell to €25.2 million from €49.7 million a year earlier, while capital expenditure was €41.3 million, or 17.5% of revenue. Sustained investment at this level could constrain cash generation and keep funding needs elevated. (PolyPeptide)
The 20.7% H1 EBITDA margin included a €9.2 million gain from selling intangible assets, and UBS cut its 2026–28 EBITDA forecasts by 3%. This tempers the headline improvement and signals that earnings growth may be less smooth than the reported figures suggest. (Investing.com)
The raised 2026 outlook assumes H2 revenue will exceed H1 and Braine will remain at target utilisation, while Strasbourg is only beginning its ramp-up and Malmö is still being commissioned. Delays or weaker utilisation could put the guidance at risk. (PolyPeptide)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
PPGN Financial Performance
Revenues and expenses
PPGN Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing PPGN
AllUSDEURGBP
Fund name | Fund size | Fr. PPGN weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.07% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.07% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.07% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.04% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.